ClinicalTrials.gg
Active, not recruitingNCT06561685Updated Nov 10, 2026

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

A Phase 1 interventional study of LY4050784 and Pembrolizumab in Metastatic Solid Tumor, Advanced Solid Tumor and Non-small Cell Lung Cancer, sponsored by Eli Lilly and Company. Active, not recruiting at 32 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

How we know · 20 judgments

Updated Nov 10, 2026Now Active, not recruiting1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
340
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 72 studies in Neoplasm Metastasis by Eli Lilly and Company — 7 open to participants now, 16 under way, 7 of them phase 3. Neoplasm Metastasis · Eli Lilly and Company.

Planned enrollment
14th of 66
340 · median 77
Started
2024
with 3 others
Phase 1
43 of 72
3 open now
Primary completion
2027-10
later than 8 of 15 live
Registered
65th of 72
by date

Among the 72 studies in Neoplasm Metastasis by Eli Lilly and Company, this one is the 14th largest by planned enrollment of the 66 interventional ones that give a count, is one of 4 that started in 2024, is one of 43 in phase 1, reaches primary completion later than 8 of the 15 other live ones, and was the 65th registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

7 of the 72 studies in Neoplasm Metastasis by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Neoplasm Metastasis by Eli Lilly and Company, or all of them as a file.
02

Study summary

The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with other anticancer agents. In addition, with locally advanced or metastatic solid tumors with a BRG1 (Brahma-related gene 1, also known as SMARCA4) alteration who have previously received, do not qualify for, or are refusing standard of care treatments, or there is no standard therapy available for the disease. The study is conducted in two parts - phase Ia (dose-escalation) and phase Ib (dose-optimization, dose-expansion). The study will last up to approximately 4 years.

03

Conditions studied

  • Metastatic Solid Tumor
  • Advanced Solid Tumor
  • Non-small Cell Lung Cancer
  • SMARCA4-Deficient Tumor

Keywords

  • SMARCA2
  • SMARCA4
  • Lung cancer
  • BRM
  • BRG1
  • Adenocarcinoma
  • Squamous cell carcinoma
  • Targeted therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have one of the following locally advanced or solid tumor with SMARCA4 (BRG1) alteration:

    • Phase 1a dose escalation: Presence of any alteration in SMARCA4 (BRG1)
    • Phase 1b expansion: Part A: Non-small Cell Lung Cancer (NSCLC) that is locally advanced and not suitable for definitive locoregional therapy, or metastatic with presence of a known or likely loss of function alteration in SMARCA4 (BRG1) or loss of protein expression.
    • Phase 1b expansion: Part B: Any tumor type (other than NSCLC) that has the presence of a known or likely loss of function alteration in SMARCA4 (BRG1) or loss of protein expression.
    • Phase 1b expansion: Part C: Non-small Cell Lung Cancer (NSCLC) that is locally advanced and not suitable for definitive locoregional therapy, or metastatic with presence of a known or likely loss of function alteration in SMARCA4 (BRG1) or loss of protein expression.
  • Prior Systemic Therapy Criteria:

    • Phase 1a dose escalation and Phase 1b (Part B): Participants who received all standard therapies for which the individual was deemed to be an appropriate candidate by the treating Investigator; or the individual is refusing the remaining most appropriate standard of care treatment; or there is no standard therapy available for the disease.
    • Phase 1b expansion (Part A): Participants must have received at least one for advanced or metastatic disease.
    • Phase 1b expansion (Part C): Participants may be treatment naïve or have received therapy for advanced or metastatic disease
  • Measurability of disease

    • Phase 1a dose escalation (excluding backfill): measurable or non- as defined by v1.1 (RECIST v1.1)
    • Phase 1a backfill and Phase 1b expansion: Measurable disease required as defined by RECIST v1.1
  • Have an (ECOG) performance status score of 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Participants with known or likely loss of function alteration of SMARCA2 (BRM) or with known association with SMARCA2 (BRM) alterations
  • Prior exposure to SMARCA2 (BRM) inhibitor(s) and/or degrader(s) (prior exposure may be permitted for dose escalation)
  • Participants with known or suspected history of untreated or uncontrolled central nervous system (CNS) involvement
  • Participants with history of increased risk of prolonged or significant arrythmia
  • Significant cardiovascular disease
  • Participants with active and/or treated for an additional primary malignancy within 2 years prior to enrolment
  • Participants who are pregnant, breastfeeding or plan to breastfeed or expecting to conceive or father children during study or within 6 months after the last dose of study intervention
  • Participants with history of active diseases, history of allogenic stem cell/organ transplant or compromised immune system within past 2 years (Part C only)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
340 participants (estimated)

Study arms

  • Experimental
    LY4050784 (Phase 1a - Dose Escalation)

    Escalating doses of LY4050784 administered orally.

    Drug: LY4050784

  • Experimental
    LY4050784 (Phase 1b - Dose Optimization/Part A)

    Comparing 2 or more doses (evaluated during dose escalation) of LY4050784 administered orally.

    Drug: LY4050784

  • Experimental
    LY4050784 (Phase 1b - Dose Expansion/Part B)

    LY4050784 administered orally.

    Drug: LY4050784

  • Experimental
    LY4050784 (Phase 1b - Dose Expansion/Part C) Cohort C1

    LY4050784 administered orally in combination in combination with pembrolizumab administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met.

    Drug: LY4050784 · Drug: Pembrolizumab

  • Experimental
    LY4050784 (Phase 1b - Dose Expansion/Part C) Cohort C2a

    LY4050784 administered orally in combination in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met.

    Drug: LY4050784 · Drug: Pembrolizumab · Drug: Cisplatin · Drug: Carboplatin · Drug: Pemetrexed

  • Experimental
    LY4050784 (Phase 1b - Dose Expansion/Part C) Cohort C2b

    LY4050784 administered orally in combination in combination with pembrolizumab, paclitaxel/nab-paclitaxel and carboplatin administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met.

    Drug: LY4050784 · Drug: Pembrolizumab · Drug: Carboplatin · Drug: Paclitaxel · Drug: Nab paclitaxel

Interventions

06

What researchers measure

Primary outcomes

  1. Phase Ia: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs), and Adverse Event(s) (AEs)

    A summary of TEAEs, SAEs, and AEs regardless of causality, will be reported in the Reported Adverse Events module

    Time frame: Up to Approximately 48 Months or 4 Years

  2. Phase 1a: To determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of LY4050784

    Number of participants with dose-limiting toxicities (DLTs)

    Time frame: Up to Approximately 48 Months or 4 Years

  3. Phase 1b: To assess the antitumor activity of LY4050784 Monotherapy: Overall response rate (ORR)

    ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1)

    Time frame: Up to Approximately 48 Months or 4 Years

  4. Phase 1b (Dose optimization only): To confirm the RP2D/optimal dose based on safety and efficacy of LY4050784

    A summary of TEAEs, SAEs, and AEs regardless of causality, will be reported in the Reported Adverse Events module, ORR and Duration of Response (DOR) per Investigator

    Time frame: Up to Approximately 48 Months or 4 Years

  5. Phase 1b (Combination cohorts/Part C): To assess the safety and tolerability of LY4050784 when administered in combination with other anticancer agents

    A summary of TEAEs, SAEs, and AEs regardless of causality, will be reported in the Reported Adverse Events module

    Time frame: Up to Approximately 48 Months or 4 Years

Secondary outcomes

  1. To characterize the pharmacokinetics (PK) properties of LY4050784: Maximum Concentration (Cmax)

    PK: Cmax of LY4050784

    Time frame: Cycle 1 (Day 8)

  2. To characterize the PK properties of LY4050784: Time to Maximum Concentration (Tmax)

    PK: Tmax of LY4050784

    Time frame: Cycle 1 (Day 8)

  3. To characterize the PK properties of LY4050784: Area under the concentration versus time curve (AUC)

    PK: AUC of LY4050784

    Time frame: Cycle 1 (Day 8)

  4. Phase Ia: To evaluate the preliminary antitumor activity of LY4050784: Overall response rate (ORR)

    ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1)

    Time frame: Up to Approximately 48 Months or 4 Years

  5. To evaluate the preliminary antitumor activity of LY4050784: Duration of response (DOR)

    DOR per investigator assessed RECIST 1.1

    Time frame: Up to Approximately 48 Months or 4 Years

  6. To evaluate the preliminary antitumor activity of LY4050784: Time to response (TTR)

    TTR per investigator assessed RECIST 1.1

    Time frame: Up to Approximately 48 Months or 4 Years

  7. To evaluate the preliminary antitumor activity of LY4050784: Disease control rate (DCR)

    DCR per investigator assessed RECIST 1.1

    Time frame: Up to Approximately 48 Months or 4 Years

  8. To evaluate the preliminary antitumor activity of LY4050784: Progression free survival (PFS)

    PFS per investigator assessed RECIST 1.1

    Time frame: Up to Approximately 48 Months or 4 Years

  9. To evaluate the PK properties of LY4050784 in combination cohorts: Maximum Concentration (Cmax) PK: Cmax of LY4050784

    Time frame: Cycle 1 (Day 8)

  10. To evaluate the PK properties of LY4050784 in combination cohorts: Time to Maximum Concentration (Tmax) PK: Tmax of LY4050784

    Time frame: Cycle 1 (Day 8)

  11. To evaluate the PK properties of LY4050784 in combination cohorts: Area under the concentration versus time curve (AUC)

    Time frame: Cycle 1 (Day 8)

07

Study locations

32 sites
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Oct 2027, 37 months after the start.

Of 289 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's planned 37 months is below that.

Counting every sponsor, half of 498 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2024
First posted
Aug 20, 2024
StartActual
Sep 19, 2024
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2027
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 10, 2026
Sites
1 site removed
Show 1 removed
  • Aichi Cancer Center Hospital · Nagoya, Japan
Nov 4, 2026
Show all 2 updates
  1. Nov 10, 2026
    Recruiting→Active, not recruiting
    + 2 other changes: contact details and site details
  2. Nov 4, 2026
    1 site removed
    Show 1 removed
    • Aichi Cancer Center Hospital · Nagoya, Japan
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06561685
Responsible party
Sponsor
First posted
Aug 20, 2024
Start date
Sep 19, 2024
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion